Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 4Completed 4Active not recruiting 3Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 7Gastrointestinal 6Other hematologic neoplasm 5Thoracic 4Breast 4Genitourinary 3Tumor-Agnostic 2Myeloid 2Gynecologic 2Lymphoid 1Dermatologic 1CNS 1

Conditions

Uveal Melanoma 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 58Cyclophosphamide 53Ipilimumab 52Nivolumab 44aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 18dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11Filgrastim 10Dacarbazine 10spartalizumab 9cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Injections × Dermatologic × Clear all
NCT05047536 2025-12-19

KZR-261 in Subjects With Advanced Solid Malignancies

Kezar Life Sciences, Inc.

Phase 1 Terminated
61 enrolled 25 charts
DermatologicGastrointestinalOther solid neoplasmThoracic

Uveal Melanoma, Melanoma, Mesothelioma, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡